Introduction

Sleep disturbances are among the most common complaints encountered in primary care. Melatonin, an endogenous hormone regulating circadian rhythms, is widely used as a nonprescription sleep aid. Its perceived safety and “natural” origin contribute to extensive unsupervised use. However, variability in product quality, uncertainty regarding dosing, potential interactions, and limited long-term data create challenges for clinicians. A structured understanding of melatonin’s benefits and risks alongside evidence-based behavioral treatments for insomnia is essential for appropriate patient counseling.

Pharmacology and Mechanism of Action

Melatonin is synthesized in the pineal gland and secreted in response to darkness, signaling circadian night. It acts primarily through MT1 and MT2 receptors in the suprachiasmatic nucleus, facilitating sleep initiation and circadian phase regulation. Exogenous melatonin has chrono biotic effects, shifting circadian timing when administered appropriately relative to endogenous secretion. Immediate-release formulations primarily reduce sleep latency, whereas prolonged-release formulations may improve sleep maintenance.1

Clinical Evidence for Efficacy

Evidence supports melatonin for circadian rhythm sleep-wake disorders, including delayed sleep phase disorder and jet lag. A clinical practice guideline reported modest reductions in sleep onset latency and improved sleep timing in these conditions.1 Evidence for primary insomnia is mixed, with generally modest benefits compared with behavioral interventions. In older adults, prolonged-release formulations may improve sleep quality modestly.2

Pediatric use has increased, particularly among children with neurodevelopmental disorders. Studies suggest improvements in sleep onset and duration, although optimal dosing and long-term safety remain uncertain.3

Safety and Adverse Effects

Melatonin is generally well tolerated. Common adverse effects include daytime somnolence, headache, dizziness, and nausea. Systematic reviews report low rates of serious adverse events.4 Higher doses may increase sedation and impair psychomotor performance.5 Rare reports describe vivid dreams, mood changes, or hypotension.

Melatonin is marketed as a dietary supplement in the United States and is not subject to the same regulatory standards as prescription medications. Analyses of commercial products reveal substantial variability in labeled content and occasional contamination.2

Drug Interactions

Melatonin may interact with several medication classes through pharmacodynamic and pharmacokinetic mechanisms. Sedative effects may be potentiated when combined with central nervous system depressants, including benzodiazepines, opioids, or alcohol.6 Concomitant use with antidepressants or antipsychotics may increase sedation or alter circadian regulation.

Melatonin can influence platelet aggregation and may increase bleeding risk when used with anticoagulants or antiplatelet agents.7 Additionally, metabolism via cytochrome P450 enzymes suggests potential interactions with medications affecting CYP1A2 activity, such as fluvoxamine or certain antibiotics. Careful medication reconciliation is therefore essential when patients report melatonin use.

Special Populations

Children and Adolescents

Melatonin is commonly used for pediatric insomnia, especially in neurodevelopmental disorders. Short-term studies indicate effectiveness for sleep initiation; however, long-term safety data are limited. Concerns include potential effects on pubertal development due to hormonal interactions.3 Use should ideally occur under specialist guidance.

Pregnancy and Lactation

Data regarding safety in pregnancy and breastfeeding are insufficient. Current evidence does not support routine use outside research settings.8

Long-Term Use

Long-term safety data are limited but generally reassuring. Observational studies and pharmacovigilance analyses suggest low rates of serious adverse outcomes with chronic use, although controlled long-duration trials are lacking.9,10 Periodic reassessment of ongoing need is recommended, with emphasis on nonpharmacologic therapies for persistent insomnia.

Cardiovascular and Metabolic Considerations

Melatonin influences circadian regulation of blood pressure, glucose metabolism, and autonomic function. Some studies suggest modest nocturnal antihypertensive effects, whereas others raise concerns about potential arrhythmias or interactions with cardiovascular medications.11 A large cohort study found no clear increase in major cardiovascular events among supplement users, although confounding factors limit interpretation.12 Overall, evidence neither strongly supports nor contraindicates use in most cardiovascular patients, but caution is warranted in individuals with unstable cardiac conditions.

Supplement Quality and Regulation

Because melatonin products are sold as dietary supplements, manufacturing standards vary widely. Independent testing has demonstrated discrepancies between labeled and actual melatonin content and the presence of impurities.2 Recommending products that undergo third-party quality testing may reduce risk.

Behavioral Therapy and Sleep Hygiene

Nonpharmacologic treatment remains the cornerstone of management for chronic insomnia. Current guidelines recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for persistent insomnia. CBT-I incorporates structured strategies to modify maladaptive sleep behaviors, regulate sleep–wake schedules, reduce physiologic and cognitive arousal, and challenge dysfunctional beliefs about sleep. These interventions typically include stimulus control, sleep restriction therapy, relaxation techniques, and cognitive restructuring. Compared with pharmacologic treatments, CBT-I produces more durable improvements in sleep outcomes and is associated with fewer adverse effects.13

Basic sleep hygiene measures are also important adjuncts. These include maintaining consistent bedtimes and wake times, minimizing evening exposure to bright light and electronic screens, avoiding caffeine and heavy meals before bedtime, and optimizing the sleep environment for comfort and darkness. Pharmacologic therapies such as melatonin should generally be considered adjunctive to these behavioral approaches rather than replacements for them.

Clinical Application in Primary Care

In primary care settings, melatonin and melatonin-receptor agonists represent low-risk therapeutic options for older adults with sleep-onset insomnia. Evidence synthesized in American Family Physician demonstrates that both immediate-release and prolonged-release melatonin produce statistically significant but clinically modest improvements, reducing sleep-onset latency by approximately 7–15 minutes and increasing total sleep time by 10–13 minutes.14 Prolonged-release melatonin at a 2-mg nightly dose shows the most consistent benefit in adults over 55, with trials reporting improved sleep latency, better subjective sleep quality, and no increase in adverse effects compared with placebo.14 Ramelteon offers similar reductions in sleep-onset latency with a particularly favorable safety profile, including no observed increase in falls, fractures, or motor vehicle accidents in large Medicare cohort analyses.14 For primary care clinicians, these agents are best positioned as safe adjuncts for patients seeking non-sedating alternatives or those who are poor candidates for benzodiazepines or Z-drugs, while cognitive behavioral therapy for insomnia remains the recommended first-line intervention.

Table 1.Clinical Guidance for Melatonin Use in Primary Care
Clinical Situation Typical Dose & Timing Evidence of Benefit Safety Considerations Drug Interactions Special Guidance
Circadian rhythm sleep-wake disorders (e.g., delayed sleep phase) 0.5–5 mg 1–3 h before desired bedtime Moderate evidence for phase shifting and reduced sleep latency1 Generally well tolerated; monitor for morning sedation4 CNS depressants⁶, CYP1A2 inhibitors7 Most evidence-supported indication1
Jet lag 0.5–5 mg at destination bedtime for several nights Moderate evidence for improving sleep and daytime alertness¹ Short-term use considered safe4 Sedatives, alcohol6 Begin on arrival at destination1
Primary insomnia (adults) 1–5 mg 1–2 h before bedtime Modest benefit compared with placebo1 May cause daytime drowsiness, dizziness4 Antidepressants, antipsychotics, sedatives6 Behavioral therapy preferred first-line13
Older adults with sleep maintenance insomnia 1–2 mg prolonged-release formulation Modest improvements in sleep quality2 Increased fall risk if excessive sedation4 Antihypertensives, sedatives6 Start low, monitor closely2
Pediatric insomnia (especially neurodevelopmental disorders) 0.5–3 mg initially; up to 5 mg in selected cases Evidence for reduced sleep latency3 Limited long-term safety data3 Sedatives, stimulants6 Use under specialist guidance3
Pregnancy and lactation Not routinely recommended Insufficient evidence8 Unknown fetal and neonatal effects8 Unknown Avoid unless specialist-directed8
Long-term use Lowest effective dose Limited long-term controlled data9,10 Periodic reassessment advised9,10 Depends on concomitant medications Emphasize behavioral therapies13
Cardiovascular disease Individualized Unclear net benefit11,12 Possible effects on BP, heart rate11 Antihypertensives, anticoagulants7 Use caution in unstable disease11
Patients on anticoagulants / antiplatelets Avoid or monitor closely No direct sleep benefit evidence Possible increased bleeding risk7 Warfarin, DOACs, aspirin7 Consider alternatives7
Concurrent CNS depressants Reduce dose or avoid Additive sedation risk6 Impaired alertness, falls6 Benzodiazepines, opioids, alcohol6 Counsel regarding safety6

Conclusion

Melatonin can be a useful therapeutic option for selected sleep disorders, particularly circadian rhythm disturbances, but its widespread unsupervised use raises important safety and efficacy considerations. Primary care clinicians play a critical role in guiding appropriate dosing, identifying drug interactions, counseling special populations, and emphasizing evidence-based behavioral treatments for insomnia. Continued research is needed to clarify long-term safety, cardiovascular effects, and optimal clinical use.